Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of June 2026, specifically dated June 11, 2026. The report details the execution of a new Sales Agreement for an "at the market" (ATM) equity offering.
Key Financial Metrics
The filing does not provide operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to the potential capital raise:
- Maximum Offering Amount: Up to $2,926,500 in aggregate offering price.
- Commission Fee: 3.0% of gross proceeds payable to the agent.
Material Changes
The primary material event is the entry into a Sales Agreement with A.G.P./Alliance Global Partners on June 11, 2026. This agreement authorizes the company to sell its ordinary shares through an ATM offering. No other material changes to operations or financial status are reported in this document.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The company is not obligated to sell any shares under the agreement. There is no assurance regarding the price, number of shares, or timing of any potential sales. The agent will use commercially reasonable efforts to sell shares based on the company's instructions.
Risks and Contingencies:
- Sales are subject to market conditions and the company's discretion.
- The agreement may be terminated by either party as set forth in the contract.
- The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price to assess potential dilution from the $2,926,500 offering cap.
- Review the full Sales Agreement (Exhibit 10.1) for specific termination clauses and pricing parameters.
- Check subsequent filings to determine if and when shares are actually sold under this ATM program.
- Confirm the status of the underlying shelf registration statement (File No. 333-277565).